You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Multimode Organic Scintillators for Neutron/Gamma Detection

    SBC: Radiation Monitoring Devices, Inc.            Topic: DTRA19B003

    There is significant interest in multi-functional materials enabling gamma-ray spectroscopy, neutron/gamma pulse shape discrimination (PSD), ultra-fast response, and time-of-flight (TOF) neutron detection. These materials would be used in a variety of mission scenarios for the localization and monitoring of special nuclear materials. Commercial inorganic scintillators offer some of these character ...

    STTR Phase I 2020 Department of DefenseDefense Threat Reduction Agency
  2. Mixed Elpasolite Scintillators

    SBC: Radiation Monitoring Devices, Inc.            Topic: DTRA18B003

    The goal of this program is to develop the mixed elpasolite scintillators in order to achieve an energy resolution of  (≤ 2.5% (approaching 2%) at 662 keV for crystal sizes of up to 2 inch by 2 inch.  In this project we will investigate compositional changes in selected mixed-elpasolite(s) in order to achieve very high energy resolution.  By incorporating 6Li, neutron detection will also be t ...

    STTR Phase II 2020 Department of DefenseDefense Threat Reduction Agency
  3. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  4. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  5. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens, whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial and alphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable an ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  6. High Energy Resolution Mixed-Halide Elpasolite Scintillators for Next Generation RIID

    SBC: CapeSym, Inc            Topic: DTRA18B003

    The ability to discriminate between threatening and benign sources depends on the sensitivity, accuracy, and identification speed of the detection equipment. High energy resolution of the radionuclide sensor is necessary to decrease the likelihood of false identification. However, few scintillators achieve better than 3% energy resolution at 662 keV, and none exceed 2.5%. The goal of this effort i ...

    STTR Phase II 2020 Department of DefenseDefense Threat Reduction Agency
  7. A Novel, Microscale, Distributable Sensor Technology for Ionizing Radiation

    SBC: CFD Research Corporation            Topic: DTRA14B004

    Terrorist use of radioactive nuclear materials via nuclear and/or radiological dispersion devices (dirty bombs) is a serious threat. Therefore, it is crucial to detect proliferation of nuclear material. Critical challenges include: (a) high sensitivity detection of signature emissions from radioactive isotopes, and (b) cost-effectiveness for deployment of sensor networks across large storage facil ...

    STTR Phase II 2019 Department of DefenseDefense Threat Reduction Agency
  8. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government